Sandoz’s Bio100 targets 100+ biosimilars by 2040
Bio100 plans to grow the biosimilar portfolio to over 100 by 2040 and target 80% LoE coverage. It targets mid- to high single-digit sales growth through 2030, doubling net sales by 2035 and core EBITDA margin above 30%.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.